TRIMEDYNE RECEIVES FDA CLEARANCE TO MARKET NEW LASER DEVICE

FOR IMMEDIATE RELEASE

CONTACT: Jeffrey Rudner
(949) 951-3800, Ext. 285
jrudner@trimedyne.com

January 5, 2006 – Irvine, CA: TRIMEDYNE, INC. (OTCBB "TMED") today announced it received Food and Drug Administration (FDA) clearance to market its new VaporMAX™ Fiber for use with its Holmium Lasers for their FDA cleared indications, including the treatment of enlarged prostates, technically called benign prostate hyperplasia or BPH. The clearance also covers marketing the new VaporMAX Fiber for use with Holmium Lasers with a compatible connector made by others.

BPH affects more than 50% of men over age 55, and approximately 200,000 procedures to treat BPH are performed each year in the United States. The new Fiber qualifies for reimbursement under the higher-paying APC Code Number 3525.

Trimedyne's new VaporMAX™ Side-Firing Laser Fibers vaporize an average of 3 grams of soft tissue per minute over 60 minutes of use, which is faster than other currently marketed laser devices, based on laboratory testing of animal tissue and published data. A faster vaporization rate minimizes both physician and operating room time. Testing also indicates the new VaporMAX Fibers are more durable than other side-firing laser fibers, meaning that one device should be sufficient to treat even large prostates.

Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. Trimedyne has an extensive portfolio of patents covering side-firing technologies. For product, financial and other information, visit Trimedyne's website, **http://www.trimedyne.com.**

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.

* * * *